Bank of New York Mellon Increases Substantial Holding Post-Reverse Split
ATHE sits 85% above its 52-week low of $2.66.
Summary
The Bank of New York Mellon, as ADR depositary, increased its reported substantial holding in Alterity Therapeutics to 27.23% post-reverse split, reflecting a higher aggregate proportion of shares held as ADRs.
Key Events · Ownership and Investor Activity · ATHE
-
Substantial Holding Increased
The Bank of New York Mellon Corporation, as ADR depositary, increased its reported substantial holding from an adjusted 26.22% to 27.23% of ordinary shares.
-
Post-Split Adjustment
The reported change accounts for the company's recent 1-for-50 reverse stock split, showing a net increase in the depositary's equivalent share count.
-
Reversal of Trend
This increase reverses a previously reported decline in the ADR depositary's percentage ownership.
Analysis · ATHE · Life Sciences
This filing indicates that The Bank of New York Mellon Corporation, in its capacity as the ADR depositary, has increased its reported substantial holding in Alterity Therapeutics. After adjusting for the recent 1-for-50 reverse stock split, their relevant interest rose from an equivalent of 26.22% to 27.23% of the company's ordinary shares. This net increase in percentage ownership suggests a growing proportion of the company's shares are held through the ADR program, reversing a previously reported decline in ADR depositary ownership.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 28.9% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATHE was trading at $4.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $85.4M. The 52-week trading range was $2.66 to $7.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.